Design, synthesis, and characterization of urokinase plasminogen-activator-sensitive near-infrared reporter

被引:68
作者
Law, B
Curino, A
Bugge, TH
Weissleder, R
Tung, CH [1 ]
机构
[1] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA
[2] NIDCR, Proteases & Tissue Remodeling Unit, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA
来源
CHEMISTRY & BIOLOGY | 2004年 / 11卷 / 01期
关键词
D O I
10.1016/j.chembiol.2003.12.017
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The urokinase-type plasminogen activator (uPA) plays a critical role in malignancies, and its overexpression has been linked to poor clinical prognosis in breast cancer. The ability to noninvasively and serially map uPA expression as a biomarker would thus have significant potential in improving novel cancer therapies. Here, we describe the development of a selective uPA activatable near-infrared (NIR) fluorescent imaging probe. The probe consists of multiple peptide motifs, GGSGRSANAKC-NH2, terminally capped with different NIR fluorochromes (Cy5.5 or Cy7) and a pegylated poly-L-lysine graft copolymer. Upon addition of recombinant human uPA to the probe, significant fluorescence amplification was observed, up to 680% with the optimized preparation. No activation with negative control compounds and uPA inhibitors could be measured. These data indicate that the optimized preparation should be useful for imaging uPA in cancer.
引用
收藏
页码:99 / 106
页数:8
相关论文
共 33 条
  • [1] Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO
  • [2] 2-Z
  • [3] A long-circulating co-polymer in ''passive targeting'' to solid tumors
    Bogdanov, A
    Wright, SC
    Marecos, EM
    Bogdanova, A
    Martin, C
    Petherick, P
    Weissleder, R
    [J]. JOURNAL OF DRUG TARGETING, 1997, 4 (05) : 321 - &
  • [4] In vivo molecular target assessment of matrix metalloproteinase inhibition
    Bremer, C
    Tung, CH
    Weissleder, R
    [J]. NATURE MEDICINE, 2001, 7 (06) : 743 - 748
  • [5] PHYSIOLOGICAL CONSEQUENCES OF LOSS OF PLASMINOGEN-ACTIVATOR GENE-FUNCTION IN MICE
    CARMELIET, P
    SCHOONJANS, L
    KIECKENS, L
    REAM, B
    DEGEN, J
    BRONSON, R
    DEVOS, R
    VANDENOORD, JJ
    COLLEN, D
    MULLIGAN, RC
    [J]. NATURE, 1994, 368 (6470) : 419 - 424
  • [6] Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma
    Casella, R
    Shariat, SF
    Monoski, MA
    Lerner, SP
    [J]. CANCER, 2002, 95 (12) : 2494 - 2499
  • [7] Duffy MJ, 1999, J SURG ONCOL, V71, P130, DOI 10.1002/(SICI)1096-9098(199906)71:2<130::AID-JSO14>3.0.CO
  • [8] 2-9
  • [9] Cancer - Proteases - invasion and more
    Edwards, DR
    Murphy, G
    [J]. NATURE, 1998, 394 (6693) : 527 - 528
  • [10] Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay
    Ferno, M
    Bendahl, PO
    Borg, A
    Brundell, J
    Hirschberg, L
    Olsson, H
    Killander, D
    [J]. EUROPEAN JOURNAL OF CANCER, 1996, 32A (05) : 793 - 801